Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Patent
1996-01-18
1998-11-24
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
424489, 424480, 424495, 424488, 494486, 494487, A61K 920
Patent
active
058403329
ABSTRACT:
A gastrointestinal delivery system is provided. The system comprises a drug in combination with a core material, the core being surrounded by a water-insoluble or relatively water-insoluble coating material in which particulate water-insoluble material is embedded. When the delivery device enters the gastrointestinal tract, the particulate matter takes up liquid, thus forming channels interconnecting the drug-containing core with the outside of the delivery device. These channels allow the release of drug from the core into the gastrointestinal tract. By controlling parameters in the device, such as the core material, carrier material in the coating, and particulate matter, the location of release of the drug can be carefully controlled. Thus, the invention is also directed to a method of using the device for the treatment of disease by the release of drugs in the gastrointestinal tract in a location- and time- dependent manner.
REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3921636 (1975-11-01), Zaffaroni
patent: 4327725 (1982-05-01), Cortese et al.
patent: 4486471 (1984-12-01), Samejima et al.
patent: 4503030 (1985-03-01), Edgren et al.
patent: 4610870 (1986-09-01), Jain et al.
patent: 4627850 (1986-12-01), Deters et al.
patent: 4863744 (1989-09-01), Urquhart et al.
patent: 4904474 (1990-02-01), Theeuwes et al.
patent: 4983401 (1991-01-01), Eichel et al.
patent: 5422121 (1995-06-01), Lehmann et al.
patent: 5445829 (1995-08-01), Paradissis et al.
English language translation of German Patent Application No. 43 18 375 A1.
Bartalsky, A., "Salicylazobenzoic Acid in Ulcerative Colitis," Lancet 1:960 (1982).
Brown, J. P. et al., "A Polymeric Drug for Treatment of Inflammatory Bowel Disease," J. Med. Chem. 26:1300-1307 (1983).
Cummings, J. H. et al., "Fermentation in the human large intestine and the available substrates," Am. J. Clin. Nutr. 45:1243-1255 (1987).
Cummings, J. H. et al., "Progress Report: Laxative Abuse," Gut 15:758-766 (1974).
Fairbairn, J. W. et al., "The Active Constituents of the Vegetable Purgatives Containing Anthracene Derivatives," J. Pharm. Pharmacol. 1:683-694 (1949).
Friend, D. R. et al., "Drug Glycosides: Potential Prodrugs for Colon-Specific Drug Delivery," J. Med. Chem. 28:51-57 (1985).
Friend, D. R. et al., "A Colon-Specific Drug-Delivery System Based on Drug Glycosides and the Glycosidases of Colonic Bacteria," J. Med. Chem. 27:261-266 (1984).
Gassmann, B. et al., "Pharmaceutical composition with delayed activity release," Chemical Abstracts 103(22), Abstract No. 183574c (1985).
Gullikson, G. W. et al., "Mechanisms of Action of Laxative Drugs," in Pharmacology of Intestinal Permeation II, Csaky, T. Z. (ed.), Springer-Verlag, Heidelberg, pp. 419-459 (1984).
Hardcastle, J. D. et al., "The action of sennosides and related compounds on human colon and rectum," Gut 11:1038-1042 (1970).
Ishino, R. et al., "Absorption of Diltiazem in Beagle Dog from Pulsatile Release Tablet," Chem. Pharm. Bull. 40(11):3094-3096 (1992).
Ishino, R. et al., "Design and Preparation of Pulsatile Release Tablet as a New Oral Drug Delivery System," Chem. Pharm. Bull. 40(11):3036-3041 (1992).
Klotz, U., "Clinical Pharmacokinetics of Sulphasalazine, Its Metabolites and Other Prodrugs of 5-Aminosalicylic Acid," Clin. Pharmacokin. 10:285-302 (1985).
Lancaster, C. M. et al., "Drug Delivery to the Colon: Polymer Susceptibility to Degradation by Colon Contents," Polymer Prep. 30:480-481 (1989).
Lehmann, K.D.R. et al., "Methacrylate-Galactomannan Coating for Colon-Specific Drug Delivery," Proceedings and Program of the 18th International Symposium on Controlled Release of Bioactive Materials, Kellaway, I.W. ed., Controlled Release Society, Inc. pub., Jul. 8-11, 1991, Amsterdam, The Netherlands.
Levine, D. S. et al., "Coating of Oral Beclomethasone Dipropionate Capsules With Cellulose Acetate Phthalate Enhances Delivery of Topically Active Antiinflammatory Drug to the Terminal Ileum," Gastroenterology 92:1037-1044 (1987).
Mardini, H. A. et al., "Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis," Gut 28:1084-1089 (1987).
Mirelman, D. et al., "Effects of Covalently Bound Silica-Nitroimidazole Drug Particles on Entamoeba histolytica," J. Infect. Dis. 159(2):303-309 (1989).
Moreto, M. et al., "3,3-Bis-(4-hydroxyphenyl)-7-methyl-2-indolinone (BHMI), the Active Metabolite of the Laxative Sulisatin," Arzneim.-Forsch./Drug Res. 29(II) (10):1561-1564 (1979).
Otsuka, M. et al., "Controlled Drug Release of Highly Water-Soluble Pentoxifylline from Time-Limit Disintegration-Type Wax Matrix Tablets," Pharm. Res. 11(3):351-354 (1994).
Rachmilewitz, D., "Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial," Brit. Med. J. 298:82-86 (1989).
Rasmussen, S. N. et al., 5-Aminosalicylic Acid in a Slow-Release Preparation: Bioavailability, Plasma Level, and Excretion in Humans, Gastroenterology 83:1062-1070 (1982).
Rubinstein, A., "Microbially Controlled Drug Delivery to the Colon," Biopharm. & Drug Dispos. 11(6):465-475 (1990).
Saffran, M., "Oral insulin in diabetic dogs," J. Endocrin. 131(2):267-278 (1991).
Saffran, M. et al., "Oral insulin in Diabetic Dogs," Diabetes 38S:81A, Abstract No. 324 (1989).
Saffran, M. et al., "Vasopressin, A Model for the Study of Effects of Additives on the Oral and Rectal Administration of Peptide Drugs," J. Pharm. Sci. 77(1):33-38 (1988).
Saffran, M. et al., "A New Approach to the Oral Administration of Insulin and Other Peptide Drugs," Science 233:1081-1084 (1986).
Salyers, A. A. et al., "Cellular Location of Enzymes Involved in Chondroitin Sulfate Breakdown by Bacteroides thetaiotaomicron," J. Bacteriol. 143(2):772-780 (1980).
Salyers, A. A. et al., "Energy sources of major intestinal fermentative anaerobes," Amer. J. Clin. Nutr. 32:158-163 (1979).
Simpkins, J. W. et al., "Evidence for the Delivery of Narcotic Antagonists to the Colon as their Glucuronide Conjugates," J. Pharmacol. Exper. Therap. 244(1):195-205 (1988).
Willoughby, C. P. et al., "Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis," Gut 23:1081-1087 (1982).
Supplementary European Search Report to Accompany European Application No. 91 91 0743.3, completed Aug. 11, 1993.
Flashner Moshe
Lerner E. Itzhak
Penhasi Adel
Benston, Jr. William E.
Page Thurman K.
Perio Products Ltd.
LandOfFree
Gastrointestinal drug delivery system does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gastrointestinal drug delivery system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gastrointestinal drug delivery system will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1699395